Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Thymosin Alpha 1 vs KPV

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

vs

Thymosin alpha-1 and KPV are both filed under immune support, but their evidence sits at opposite ends. Thymosin alpha-1 has decades of human trials and approvals abroad. KPV, a three-amino-acid fragment of alpha-MSH, has been studied in cells and mice.

Thymosin Alpha 1
Immune~2 hours

Thymosin Alpha 1 (Tα1, CAS 62304-98-7, molecular weight 3108 Da) is a 28-amino-acid acetylated peptide naturally produced by the thymus gland, approved in 35 countries under the brand name Zadaxin. The US restricted it from compounding pharmacies, creating a regulatory contradiction that defines its story. It binds Toll-like receptors TLR2 and TLR9 on dendritic cells, triggering downstream T-cell differentiation and NK cell activation through MyD88-dependent signaling. The clinical dose is 1.6 mg (1600 mcg) subcutaneously twice weekly, established by decades of Zadaxin prescribing data. The hepatitis B trials built the evidence base. A Phase III RCT (PMC4688733) showed HBeAg seroconversion at 30 to 40% versus 18% on placebo at 12 months. The Dinetz and Lee 2024 review (PMID 38308608) pulled together 30+ trials enrolling 11,000+ subjects and found consistent immune activation across indications. A separate 2024 meta-analysis (PMID 39648386) of 39 RCTs in acute COPD exacerbations (3,329 patients) confirmed improved FEV1, oxygenation, and reduced hospital stay. Community use has expanded well past hepatitis. Longevity practitioners, long COVID patients, and ME/CFS communities use the same 1600 mcg twice-weekly protocol for T-cell restoration. The practical limitation: Tα1 produces no subjective "feel." Bloodwork (CBC with differential, CD4/CD8 ratio) is the only way to confirm it's working. The TESTS Phase 3 sepsis trial (PMID 39814420, n=1,106) missed its primary mortality endpoint (HR 0.99, p=0.93). That null result is worth knowing. It didn't undermine the hepatitis or immune-support evidence, but it set a boundary on what Tα1 can do in acute critical care.

View full guide →
KPV
Immune~30 min plasma (functional anti-inflammatory activity persists 4-6 hours)

KPV (Lysine-Proline-Valine, CAS 67727-97-3) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone and one of the most discussed anti-inflammatory peptides in the gut health community. It doesn't bind melanocortin receptors the way full-length alpha-MSH does. Instead, it enters cells through PepT1, a di/tripeptide transporter expressed in the small intestine. The targeting gets interesting during active inflammation. PepT1 expression increases in inflamed colonic epithelium, confirmed in both Caco2-BBE cell lines and mouse colitis models (Dalmasso et al., Gastroenterology 2008, PMID 18061177). Inflamed tissue absorbs more KPV than healthy tissue. Once inside the cell, KPV inhibits NF-kB nuclear translocation at nanomolar concentrations, cutting production of TNF-alpha, IL-1beta, IL-6, and IL-8. Community use mirrors the preclinical rationale almost exactly. Oral dosing at 500 to 1,500 mcg per day on an empty stomach is the standard protocol for IBD, IBS, and leaky gut. Subcutaneous injection at 200 to 500 mcg per day covers systemic inflammation. The BPC-157 stack is the most discussed combination; KPV handles the inflammatory signaling while BPC-157 drives mucosal repair. Multiple integrative medicine clinics recommend this pairing. The honest limitation: every dose recommendation comes from mouse data extrapolation and community trial-and-error. No human pharmacokinetic study has measured oral bioavailability. No dose-finding trial has been completed. The plasma half-life (~30 minutes) is estimated from alpha-MSH family kinetics, not from direct KPV measurement. Fifteen PubMed papers cover this peptide. The FDA has stated it lacks human exposure data for any administration route. That gap between clean preclinical science and absent human validation defines where KPV sits right now.

View full guide →

At a Glance

Thymosin Alpha 1 moleculeThymosin Alpha 1KPV moleculeKPV
CategoryImmuneImmune
Safety GradeAC
Half-Life~2 hours~30 min plasma (functional anti-inflammatory activity persists 4-6 hours)
RouteSubcutaneousSubcutaneous or Oral
Vial Sizes5 mg, 10 mg5 mg
Beginner Dose1.6 mg 2x/week200 mcg Daily
Moderate Dose1.6 mg 2x/week500 mcg Daily
Aggressive Dose1.6 mg 3x/week1 mg Daily
Dosing SourceClinical TrialSpeculative
Side EffectsOrgan transplant recipients on immunosuppressive therapy face the most serious risk. Tα1 activates the T-cell signaling pathways that calcineurin inhibitors (cyclosporine, tacrolimus) suppress. In that population, immune activation can trigger acute graft rejection. This is an absolute contraindication. Autoimmune flare acceleration is documented in community and clinic reports. Hashimoto's patients have reported thyroid antibody titer spikes after starting Tα1. MS patients have reported flare acceleration. Lupus patients carrying antinuclear antibodies should check inflammatory markers (CRP, ESR, ANA) before starting and should not use Tα1 during active flare. The confusing part: autoimmune patients actually have lower serum thymosin alpha-1 levels (PMID 27350088). That makes supplementation seem logical, but Tα1's immune-priming action feeds the same T-cell pathways driving the flare. Published trial safety data across 11,000+ subjects shows a mild profile in non-autoimmune populations. Injection site redness and soreness occur in 5 to 18% of patients across trials. Transient fatigue occurs in 3 to 8%. Flu-like symptoms are rare and resolve within 24 to 48 hours. Myalgia reached 5% in one oncology loading-dose study. ME/CFS and post-viral patients should know about the first-dose immune reaction. A subset experiences 24 to 48 hours of symptom exacerbation after the initial injection. This is an immune activation event, not an allergic reaction. Starting at 750 to 1000 mcg for the first two injections before escalating to 1600 mcg reduces this risk. Interferon-alpha combinations (common in hepatitis protocols) can amplify flu-like side effects through additive immune stimulation. Stacking with other immune-stimulating peptides (LL-37, KPV) carries the same additive activation risk; space injections and start at low doses. Contraindications: pregnancy or breastfeeding (insufficient safety data), known hypersensitivity to Tα1 or formulation components, organ transplant recipients on immunosuppression, active autoimmune diseases in flare, and children under 18. When to seek medical attention: any autoimmune flare symptoms (joint pain, antibody titer rise, sustained fatigue spike), signs of graft rejection in transplant patients, high-grade fever, or allergic reaction (rash, difficulty breathing).The biggest safety concern with KPV is the unknown. Zero completed human clinical trials exist. No human pharmacokinetic data. No dose-finding study. The FDA has explicitly stated it lacks human exposure information for any administration route. Every safety profile below comes from preclinical research and community reporting, not from controlled human trials. That said, the community tolerability signal is remarkably clean. Most users report no side effects at standard doses (200 to 500 mcg subcutaneous, 500 to 1,500 mcg oral). KPV is a naturally occurring tripeptide fragment, three amino acids long, which limits the immunogenicity risk that larger synthetic peptides carry. Herxheimer-like reactions in weeks 1 to 2. This is the most commonly reported negative experience, specifically among IBD and Crohn's patients. Gut symptoms temporarily worsen before improving. The community explanation is that rapid NF-kB suppression shifts the inflammatory milieu. Slow titration from 250 mcg manages this in most cases. Injection site reactions with subcutaneous administration. Mild redness and irritation at the injection site, consistent with other peptide injections. KPV has a short plasma half-life (~30 minutes), so daily injection site rotation across abdomen and thigh areas is the standard recommendation. If irritation persists despite rotation, switching to oral dosing is the typical approach. Potential immune over-suppression with concurrent medications. KPV reduces TNF-alpha, IL-1beta, and IL-6, the same cytokine targets as many IBD biologics (infliximab, adalimumab) and immunosuppressants (methotrexate, azathioprine). Stacking KPV with these medications without physician oversight risks additive immune suppression and increased infection susceptibility. This is the one genuinely serious risk in the community use pattern. Oral-specific: mild bitter taste reported with sublingual spray formulations. Some users note transient GI discomfort at higher oral doses (above 1,000 mcg), though this typically resolves within the first week. No hepatotoxicity, nephrotoxicity, or cardiovascular effects have been reported in preclinical literature or community use. No antibody formation or receptor desensitization mechanism has been identified. Pregnancy and breastfeeding: no safety data exists. Do not use. This applies to both oral and injectable forms. Children and adolescents under 18: not studied in any context. No pediatric dosing exists. Active malignancy: KPV suppresses immune surveillance pathways (NF-kB, inflammatory cytokines). Effects on tumor immune response have not been studied. Avoid until data exists. When to stop: if gut symptoms worsen and persist beyond the 2-week titration window, discontinue or reduce dose. If you experience signs of immune suppression (frequent infections, slow wound healing), stop immediately and consult a physician. If injection site reactions do not resolve with rotation, switch to oral or discontinue.

Key Differences

  • Thymosin alpha-1 is a synthetic 28-amino-acid peptide sold as Zadaxin [1]. A 2009 review counted approvals in over 35 countries for hepatitis B and C and as an immune stimulant [2].

  • Its placebo-controlled results are mixed. In a multicentre phase 3 trial, 97 people with chronic hepatitis B took 1.6 mg or placebo twice weekly for 6 months [3]. Complete response was 14% vs 4%, which missed statistical significance, and the authors said it did not confirm earlier trials.

  • In sepsis, the 1,106-patient TESTS trial found no drop in 28-day mortality, with 23.4% on thymosin alpha-1 and 24.1% on placebo [4].

  • KPV is the Lys-Pro-Val tail of alpha-MSH. In mice with peritonitis it cut the build-up of inflammatory cells, and the authors concluded it likely does not act through melanocortin receptors [6].

  • KPV's gut data is all preclinical. Given in drinking water, it reduced two kinds of chemically induced colitis in mice [7]. In human gut and immune cell lines, it entered through the PepT1 transporter. Another mouse study found faster recovery in DSS and T-cell transfer colitis [8].

  • The oral route is a mouse finding. Oral KPV helped mouse colitis in drinking water [7] and packed in hyaluronic acid nanoparticles [9]. KPV doses in use come from community reports and preclinical work, not human dosing studies.

  • Thymosin alpha-1's hepatitis trial dosed 1.6 mg twice weekly [3]. After a subcutaneous injection it peaks in 1 to 2 hours and has a half-life under 3 hours [5].

When to Choose Thymosin Alpha 1

  • Human trial data matters to you (approvals in over 35 countries per a 2009 review)[2]

  • Chronic viral hepatitis is the setting, under a doctor's care [3]

  • A twice-weekly injection fits your schedule (the hepatitis trial regimen)

When to Choose KPV

  • Gut inflammation is the focus and preclinical evidence is acceptable (mouse colitis data)[7]

  • An oral option is wanted, knowing the oral data comes from mice [9]

  • Community experience with gut use carries weight for you (community reports)

Verdict

Thymosin alpha-1 has the deeper human record, with approvals in over 35 countries as of a 2009 review [2]. Still, two placebo-controlled trials, in hepatitis B and in sepsis, missed their main goals. KPV's anti-inflammatory and gut effects hold up in mice and cell lines but have not been tested in people. Community reports use KPV for gut inflammation and thymosin alpha-1 for immune support.

Research peptides with both sides of the evidence.

Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.

Can You Stack Thymosin Alpha 1 + KPV?

Yes, commonly stacked

Community reports pair them as an immune plus anti-inflammatory stack. No study has tested the two together, and KPV has no published human safety data, so the combination rests on community experience.

Dosage Calculators

Or use the universal Peptide Calculator for any peptide.

Related Guides & Stacks

Explore all Immune peptides

Peptide Schedule Research TeamReviewed Apr 8, 20269 Citations

References

  1. [1]Zadaxin (thymosin alpha1) for the treatment of viral hepatitis (Naylor, Expert Opin Investig Drugs 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]From lab to bedside: emerging clinical applications of thymosin alpha 1 (Goldstein, Expert Opin Biol Ther 2009) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Thymosin alpha1 for chronic hepatitis B, phase III randomized placebo-controlled trial (Mutchnick et al., J Viral Hepat 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]TESTS: thymosin alpha1 for sepsis, phase 3 randomized placebo-controlled trial in 1,106 adults (BMJ 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Pharmacokinetics of subcutaneous thymosin alpha1 in healthy volunteers, three formulations (Rost et al., 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Anti-inflammatory effect of the C-terminal alpha-MSH tripeptide KPV in mouse peritonitis (Getting et al., J Pharmacol Exp Ther 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation in cell lines and mouse colitis (Dalmasso et al., Gastroenterology 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
  8. [8]Melanocortin-derived tripeptide KPV in murine models of inflammatory bowel disease (Kannengiesser et al., Inflamm Bowel Dis 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
  9. [9]Oral KPV in hyaluronic acid nanoparticles for ulcerative colitis in mice (Xiao et al., Mol Ther 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed

Frequently Asked Questions

KPV has the gut-specific data, all of it from mice and cell lines. Oral KPV reduced chemically induced colitis in mice (PMID 18061177). Thymosin alpha-1's main trials are in viral hepatitis and sepsis (PMID 10607256). Community reports favor KPV for gut use.

It has worked by mouth in mice. KPV in drinking water reduced colitis (PMID 18061177), and nanoparticle-packed KPV helped in another mouse colitis model (PMID 28143741). There is no human data on oral KPV, so oral use rests on community reports.

Thymosin alpha-1's placebo-controlled results are mixed, though a 2009 review counted approvals in over 35 countries for hepatitis B and C (PMID 19392576). A phase 3 hepatitis B trial missed significance, with 14% vs 4% complete response (PMID 10607256). The 1,106-patient TESTS sepsis trial found no mortality benefit (PMID 39814420).

Community reports pair them, thymosin alpha-1 for immune support and KPV for inflammation. No study has tested the combination, and KPV has no published human safety data. Talk to a clinician before combining either with prescription immune or anti-inflammatory drugs.

The hepatitis B trial used 1.6 mg twice weekly for 6 months (PMID 10607256). After a subcutaneous dose it peaks in 1 to 2 hours, and its half-life is under 3 hours (PMID 10027483). The sepsis trial dosed every 12 hours for 7 days (PMID 39814420).
9 references